Aliases & Classifications for Polyneuropathy

Summaries for Polyneuropathy

Disease Ontology : 12 A peripheral system disease that is characterized by is damage affecting peripheral nerves (peripheral neuropathy) in roughly the same areas on both sides of the body, featuring weakness, numbness, pins-and-needles, and burning pain.

MalaCards based summary : Polyneuropathy, also known as polyneuropathies, is related to neuropathy, inflammatory demyelinating and charcot-marie-tooth disease, type 1b, and has symptoms including neuralgia An important gene associated with Polyneuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Guidance Cues and Growth Cone Motility and Neural Crest Differentiation. The drugs Imipramine and Pregabalin have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and testes, and related phenotypes are cellular and behavior/neurological

Wikipedia : 72 Polyneuropathy (poly- + neuro- + -pathy) is damage or disease affecting peripheral nerves (peripheral... more...

Related Diseases for Polyneuropathy

Diseases in the Polyneuropathy family:

Polyneuropathy Due to Drug Chronic Polyneuropathy

Diseases related to Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 535)
id Related Disease Score Top Affiliating Genes
1 neuropathy, inflammatory demyelinating 32.8 GDAP1 MPZ PMP22
2 charcot-marie-tooth disease, type 1b 32.3 MPZ PMP22
3 neuropathy, recurrent, with pressure palsies 31.3 GDAP1 MBP MPZ PMP22
4 dejerine-sottas disease 30.5 GDAP1 MPZ PMP22
5 charcot-marie-tooth disease, type 1e 29.9 GDAP1 MPZ PMP22
6 neuropathy, congenital hypomyelinating 29.7 GDAP1 MPZ PMP22
7 charcot-marie-tooth disease, type 1f 29.4 GDAP1 MPZ PMP22 TUBB3
8 chronic inflammatory demyelinating polyneuropathy 12.3
9 polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract 12.1
10 diabetic polyneuropathy 12.1
11 critical illness polyneuropathy 12.1
12 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.0
13 polyendocrine-polyneuropathy syndrome 12.0
14 ataxia and polyneuropathy, adult-onset 11.9
15 demyelinating polyneuropathy 11.9
16 subacute inflammatory demyelinating polyneuropathy 11.9
17 paraneoplastic polyneuropathy 11.8
18 chronic polyneuropathy 11.8
19 polyneuropathy due to drug 11.8
20 polyneuropathy associated with igm monoclonal gammapathy with anti-mag 11.8
21 axonal polyneuropathy associated with igg/igm/iga monoclonal gammopathy 11.8
22 amyloidosis, hereditary, transthyretin-related 11.7
23 poems syndrome 11.7
24 polyneuropathy mental retardation acromicria premature menopause 11.7
25 aplasia of extensor muscles of fingers, unilateral, with generalized polyneuropathy 11.7
26 agenesis of the corpus callosum with peripheral neuropathy 11.7
27 charcot-marie-tooth disease, x-linked recessive, 5 11.7
28 idiopathic progressive polyneuropathy 11.6
29 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 11.6
30 chronic metabolic polyneuropathy 11.6
31 familial amyloid polyneuropathy type 1 11.6
32 chronic toxic polyneuropathy 11.6
33 juvenile-onset small-fiber polyneuropathy 11.6
34 familial amyloid polyneuropathy type ii 11.6
35 polyneuropathy in collagen vascular disease 11.6
36 alcoholic neuropathy 11.6
37 thiamine metabolism dysfunction syndrome 4 11.6
38 guillain-barre syndrome 11.5
39 mitochondrial neurogastrointestinal encephalopathy disease 11.4
40 amyloidosis, finnish type 11.3
41 autosomal dominant optic atrophy plus syndrome 11.3
42 diabetic neuropathy 11.0
43 autonomic neuropathy 11.0
44 canomad syndrome 11.0
45 giant axonal neuropathy-1 11.0
46 polyradiculoneuropathy 11.0
47 neuropathy, hereditary sensory and autonomic, type ii 11.0
48 hereditary neuropathy with liability to pressure palsy 11.0
49 charcot-marie-tooth disease, axonal, type 2v 10.9
50 lattice corneal dystrophy type ii 10.9

Graphical network of the top 20 diseases related to Polyneuropathy:



Diseases related to Polyneuropathy

Symptoms & Phenotypes for Polyneuropathy

UMLS symptoms related to Polyneuropathy:


neuralgia

MGI Mouse Phenotypes related to Polyneuropathy:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 APOA1 CD40LG CD59 GDAP1 GSN MBP
2 behavior/neurological MP:0005386 10.07 ABHD12 ACHE AKR1B1 ARSA GDAP1 MAG
3 homeostasis/metabolism MP:0005376 9.86 ABHD12 ACHE AKR1B1 APOA1 ARSA CD40LG
4 hematopoietic system MP:0005397 9.85 ABHD12 SLC25A19 ACHE ARSA CD40LG CD59
5 hearing/vestibular/ear MP:0005377 9.73 PMP22 ABHD12 ACHE ARSA MAG MBP
6 nervous system MP:0003631 9.44 ACHE ARSA CD40LG GDAP1 GSN MAG

Drugs & Therapeutics for Polyneuropathy

Drugs for Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 311)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imipramine Approved Phase 4 50-49-7 3696
2
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1 148553-50-8 5486971
3
Lenalidomide Approved Phase 4,Phase 2 191732-72-6 216326
4 Piracetam Approved Phase 4,Phase 2 7491-74-9
5
Citalopram Approved Phase 4 59729-33-8 2771
6
Cilostazol Approved Phase 4 73963-72-1 2754
7
Capsaicin Approved Phase 4,Phase 2,Phase 3 404-86-4 1548943
8
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Early Phase 1 51-84-3 187
9
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
10
Oxcarbazepine Approved Phase 4 28721-07-5 34312
11
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
12
Dopamine Approved Phase 4,Phase 3,Phase 2 51-61-6, 62-31-7 681
13
Norepinephrine Approved Phase 4,Phase 2 51-41-2 439260
14
Mexiletine Approved Phase 4,Phase 2 31828-71-4 4178
15
alemtuzumab Approved, Investigational Phase 4,Phase 2 216503-57-0
16
Nortriptyline Approved Phase 4 72-69-5 4543
17
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
19 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
20 Adrenergic Agents Phase 4,Phase 3,Phase 2
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
22 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1
24 Antidepressive Agents Phase 4,Phase 2
25 Antidepressive Agents, Tricyclic Phase 4
26 calcium channel blockers Phase 4,Phase 3,Phase 2,Phase 1
27 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
28 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Nootropic Agents Phase 4,Phase 2,Phase 3
35 Protective Agents Phase 4,Phase 2,Phase 3,Early Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2
37 Antioxidants Phase 4,Phase 2,Phase 3,Early Phase 1
38 Micronutrients Phase 4,Phase 2,Phase 3,Phase 1
39 Thioctic Acid Phase 4,Phase 2,Phase 3
40 Trace Elements Phase 4,Phase 2,Phase 3,Phase 1
41 Vitamin B Complex Phase 4,Phase 2,Phase 3
42 Vitamins Phase 4,Phase 2,Phase 3,Phase 1
43 Angiogenesis Inhibitors Phase 4,Phase 2
44 Angiogenesis Modulating Agents Phase 4,Phase 2
45 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
46 Anti-Infective Agents Phase 4,Phase 3,Phase 2
47 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
48 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
49 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
50 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 333)

id Name Status NCT ID Phase Drugs
1 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
2 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
3 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
4 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
5 Levetiracetam for Painful Polyneuropathy Completed NCT00286260 Phase 4 levetiracetam
6 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4 escitalopram
7 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
8 A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment Completed NCT01713426 Phase 4 Qutenza;Pregabalin
9 Alpha Lipoic Acid for Treatment of Diabetic Neuropathy Completed NCT02439879 Phase 4 Alpha lipoic acid
10 Botulinum Toxin in Peripheral Neuropathic Pain Completed NCT01251211 Phase 4 botulinum toxin type A
11 Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain Completed NCT01302275 Phase 4 Oxcarbazepine
12 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
13 Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus Completed NCT01408199 Phase 4 Lenalidomide
14 Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder Completed NCT00844194 Phase 4 Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 90 mg QD;Duloxetine 90 mg QD;Duloxetine 60 mg QD;Duloxetine 60 mg QD;Duloxetine 120 mg QD;Duloxetine 30 mg QD;Duloxetine 30 mg QD;Duloxetine 120 mg QD
15 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
16 Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
17 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
18 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Active, not recruiting NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
19 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
20 Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy Terminated NCT00832572 Phase 4 Ranolazine;Placebo
21 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
22 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
23 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
24 Efficacy and Safety Study of Thioctacid Oral Tablets 600mg to Treat Chinese Diabetic Patients With Distal Symmetric Polyneuropathy Unknown status NCT01224353 Phase 2, Phase 3 lipoic acid
25 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD) Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
26 Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) Unknown status NCT01289704 Phase 2, Phase 3
27 RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Completed NCT00259974 Phase 3 Rituximab
28 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
29 Actovegin® Versus Placebo in Patients With Diabetic Polyneuropathy (AV-007-IM) Completed NCT00483730 Phase 3 Deproteinised hemoderivative of calf blood (Actovegin)
30 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
31 Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy Completed NCT00927914 Phase 2, Phase 3 Ranirestat;Placebo
32 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
33 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
34 The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin Completed NCT01435655 Phase 3 tafamidis
35 An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy Completed NCT00791492 Phase 2, Phase 3 Fx-1006A
36 Neuropathic Pain Management Completed NCT01263132 Phase 3 F0434;Gabapentin
37 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
38 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
39 Safety and Efficacy Study of Fx-1006A in Patients With Familial Amyloidosis Completed NCT00409175 Phase 2, Phase 3 Fx-1006A;Placebo
40 Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy Completed NCT00101426 Phase 3 ranirestat, (AS-3201)
41 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
42 Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
43 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Completed NCT00328601 Phase 3 Thioctic Acid
44 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
45 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
46 The Effect of Diflunisal on Familial Amyloidosis Completed NCT00294671 Phase 2, Phase 3 diflunisal
47 Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy Completed NCT01450163 Phase 3 Pregabalin, Oxaliplatin;Placebo , Oxaliplatin
48 APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis Completed NCT01960348 Phase 3 patisiran (ALN-TTR02);Sterile Normal Saline (0.9% NaCl)
49 Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy Completed NCT00064623 Phase 3 Capsaicin Dermal Patch
50 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin

Search NIH Clinical Center for Polyneuropathy

Cochrane evidence based reviews: polyneuropathies

Genetic Tests for Polyneuropathy

Genetic tests related to Polyneuropathy:

id Genetic test Affiliating Genes
1 Polyneuropathy 29

Anatomical Context for Polyneuropathy

MalaCards organs/tissues related to Polyneuropathy:

39
Liver, Skin, Testes, Spinal Cord, Heart, Endothelial, Brain

Publications for Polyneuropathy

Articles related to Polyneuropathy:

(show top 50) (show all 2126)
id Title Authors Year
1
The impact of type 1 diabetes and diabetic polyneuropathy on muscle strength and fatigability. ( 28285381 )
2017
2
Diagnostic Value of the Near-Nerve Needle Sensory Nerve Conduction in Sensory Inflammatory Demyelinating Polyneuropathy. ( 28796344 )
2017
3
Hereditary Sensory Polyneuropathy, Pain Insensitivity and Global Developmental Delay due to Novel Mutation in PRDM12 Gene. ( 28050684 )
2017
4
Neuromuscular ultrasound findings in distal acquired demyelinating symmetric variant of chronic inflammatory demyelinating polyneuropathy. ( 28667663 )
2017
5
Somatic mosaicism with reversion to normality of a mutated transthyretin allele related to a familial amyloidotic polyneuropathy. ( 28508289 )
2017
6
Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. ( 28893208 )
2017
7
Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy. ( 28831691 )
2017
8
Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. ( 28296226 )
2017
9
Sonographic Findings of Polyneuropathy Associated With Cerebrotendinous Xanthomatosis: A Case Report. ( 28503466 )
2017
10
Guillain-BarrAc-like axonal polyneuropathy associated with Toscana virus infection: A case report. ( 28930847 )
2017
11
Two different causes in a patient with distal symmetric axonal polyneuropathy: Churg-Strauss syndrome and multiple myeloma, coincidental or associated with each other? ( 28332041 )
2017
12
Patterns of cutaneous nerve fibre loss and regeneration in type 2 diabetes with painful and painless polyneuropathy. ( 28914336 )
2017
13
Phlebectasia in a finger in a case of microscopic polyangiitis with peripheral polyneuropathy. ( 28838824 )
2017
14
Diagnostic challenges in POEMS syndrome presenting with polyneuropathy: A case series. ( 28566158 )
2017
15
An Isolated Case of Late-onset Amyloidogenic Transthyretin Type Familial Amyloid Polyneuropathy Associated with a Mutant Transthyretin Substituting Methionine for Valine at Position 30 Showing Latent Progressive Cardiac Involvement Confirmed by Serial Annual Electrocardiograms. ( 28090046 )
2017
16
Initial development and validation of a patient-reported symptom survey for small-fiber polyneuropathy. ( 28063957 )
2017
17
Dorsal root ganglia hypertrophy as in vivo correlate of oxaliplatin-induced polyneuropathy. ( 28837658 )
2017
18
A GJA9 frameshift variant is associated with polyneuropathy in Leonberger dogs. ( 28841859 )
2017
19
Acute demyelinating polyneuropathy induced by nivolumab. ( 28844069 )
2017
20
Severe vincristine-induced polyneuropathy in a teenager with anaplastic medulloblastoma and undiagnosed Charcot-Marie-Tooth disease. ( 28438772 )
2017
21
Post bariatric Surgery Acute Axonal Polyneuropathy: Doing Your Best is Not Always Enough. ( 28904467 )
2017
22
Cardio-Ankle Vascular Index and Indices of Diabetic Polyneuropathy in Patients with Type 2 Diabetes. ( 28573145 )
2017
23
Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: a role for CWC22. ( 28250049 )
2017
24
In vitro modelling of familial amyloidotic polyneuropathy allows quantitative detection of transthyretin amyloid fibril-like structures in hepatic derivatives of patient-specific induced pluripotent stem cells. ( 28051995 )
2017
25
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. ( 28768822 )
2017
26
A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. ( 28485075 )
2017
27
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ( 28000311 )
2017
28
Chronic inflammatory demyelinating polyneuropathy. ( 28763304 )
2017
29
Brainstem encephalitis and acute polyneuropathy associated with hepatitis E infection. ( 28899886 )
2017
30
Acute simultaneous development of brain tumour-like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis. ( 28795610 )
2017
31
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy. ( 28855494 )
2017
32
Demyelinating polyneuropathy in a case of anti-LGI1 encephalitis. ( 28073143 )
2017
33
Blink reflex role in algorithmic genetic testing of inherited polyneuropathies. ( 27422849 )
2017
34
Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic Accuracy and Correlation With Electrophysiology. ( 28574858 )
2017
35
Do we underestimate influences of diabetic mononeuropathy or polyneuropathy on hand functional performance and life quality? ( 28267271 )
2017
36
Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation. ( 28943540 )
2017
37
Long-term effects of liver transplantation on small-fiber dysfunction in Japanese transthyretin (ATTR) V30M hereditary amyloidosis with polyneuropathy (FAP). ( 28434340 )
2017
38
ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. ( 28796305 )
2017
39
A case report: Non-alcoholic Wernicke encephalopathy associated with polyneuropathy. ( 28367669 )
2017
40
The medial plantar sensory response: A sensitive marker of acute Inflammatory demyelinating polyneuropathy. ( 28934625 )
2017
41
Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. ( 28108521 )
2017
42
Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. ( 28085193 )
2017
43
Critical care polyneuropathy in burn injuries: An integrative review. ( 28838678 )
2017
44
Tafamidis for a Transplant Patient with Transthyretin Amyloid Polyneuropathy. ( 28884984 )
2017
45
De novo intraocular amyloid deposition after hepatic transplantation in familial amyloidotic polyneuropathy. ( 28900607 )
2017
46
De novo p.T362R mutation in MORC2 causes early onset cerebellar ataxia, axonal polyneuropathy and nocturnal hypoventilation. ( 28402445 )
2017
47
Transcranial Magnetic Stimulation as an Additional Diagnostic Tool in Children with Acute Inflammatory Demyelinating Polyneuropathy. ( 28904571 )
2017
48
Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. ( 28575198 )
2017
49
Functional outcome of critical illness polyneuropathy in patients affected by severe brain injury. ( 28417610 )
2017
50
Eosinophilic Granulomatosis with Polyangiitis Presented as Acute Polyneuropathy and Cerebral Vasculitis. ( 28680302 )
2017

Variations for Polyneuropathy

ClinVar genetic disease variations for Polyneuropathy:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240

Expression for Polyneuropathy

Search GEO for disease gene expression data for Polyneuropathy.

Pathways for Polyneuropathy

Pathways related to Polyneuropathy according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.5 GDAP1 GSN MAG
2 11.14 MBP MPZ PMP22
3
Show member pathways
10.43 RBP4 TTR
4 9.53 MAG MBP

GO Terms for Polyneuropathy

Cellular components related to Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 ACHE APOA1 ARSA CD40LG CD59 GSN
2 extracellular space GO:0005615 9.65 ACHE AKR1B1 APOA1 ARSA CD40LG CD59
3 myelin sheath GO:0043209 9.46 GSN MAG MBP MPZ
4 Schmidt-Lanterman incisure GO:0043220 9.26 AKR1B1 MAG
5 compact myelin GO:0043218 8.8 CD59 MAG PMP22

Biological processes related to Polyneuropathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to ethanol GO:0045471 9.58 ARSA GSN RBP4
2 negative regulation of viral entry into host cell GO:0046597 9.37 GSN IFNA2
3 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 9.32 MAG MPZ
4 glycerophospholipid catabolic process GO:0046475 9.26 ABHD12 PNPLA6
5 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.16 APOA1 MBP
6 retinoid metabolic process GO:0001523 9.13 APOA1 RBP4 TTR
7 myelination GO:0042552 8.8 MBP MPZ PMP22

Sources for Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....